Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
You may also be interested in...
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.